Generali Elena, Scirè Carlo A, Favalli Ennio G, Selmi Carlo
a Division of Rheumatology and Clinical Immunology , Humanitas Research Hospital , Milan , Italy.
b Epidemiology Unit , Italian Society for Rheumatology , Milan , Italy.
Expert Rev Clin Immunol. 2016 Jun;12(6):651-60. doi: 10.1586/1744666X.2016.1147954. Epub 2016 Feb 24.
Psoriatic arthritis (PsA) is characterized by chronic inflammation of peripheral joints and axial skeleton, associated with a strong genetic background. Clinics include enthesitis or dactylitis and extra-articular involvement as uveitis or inflammatory bowel disease, while treatment options range from nonsteroidal anti-inflammatory drugs (NSAIDs) to biologics, targeting TNF α or Th17. No serum autoantibody is associated with PsA, while other biomarkers have been proposed for early diagnosis or to predict treatment response. To better discuss this area of growing interest we performed a systematic review of the literature on biomarkers in PsA. Our research retrieved 408 papers, and 38 were included in the analysis. Based on the available literature, we draw some recommendations for the use of biomarkers in the management of patients with PsA.
银屑病关节炎(PsA)的特征是外周关节和中轴骨骼的慢性炎症,具有很强的遗传背景。临床症状包括肌腱端炎或指(趾)炎以及葡萄膜炎或炎症性肠病等关节外受累情况,而治疗选择范围从非甾体抗炎药(NSAIDs)到针对肿瘤坏死因子α(TNFα)或辅助性T细胞17(Th17)的生物制剂。银屑病关节炎不伴有血清自身抗体,不过已提出其他生物标志物用于早期诊断或预测治疗反应。为了更好地探讨这个日益受到关注的领域,我们对银屑病关节炎生物标志物的文献进行了系统综述。我们的研究检索到408篇论文,其中38篇纳入分析。基于现有文献,我们对生物标志物在银屑病关节炎患者管理中的应用提出了一些建议。